Agenus r&d update & third quarter financial report

Lexington, mass., oct. 29, 2020 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate and optimize immune response to cancers and infections, today provided a corporate update and reported financial results for the third quarter of 2020.
AGEN Ratings Summary
AGEN Quant Ranking